Bo Jia1, Shaoxuan Hu1, Jianliang Yang1, Shengyu Zhou1, Peng Liu1, Yan Qin1, Lin Gui1, Sheng Yang1, Hua Lin2, Changgong Zhang1, Puyuan Xing1, Lin Wang1, Mei Dong1, Liqiang Zhou1, Yan Sun1, Xiaohui He1, Yuankai Shi1. 1. a Department of Medical Oncology, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China. 2. b Department of Medical Record Library, Cancer Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College , No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021 , China.
Abstract
OBJECTIVES: Optimal chemotherapy regimen for peripheral T-cell lymphomas (PTCL) has not been fully defined. This study aimed to evaluate the optimal chemotherapy regimen in the first-line treatment for PTCL patients. METHODS: Between 2003 and 2014, 93 consecutive patients with PTCL were enrolled in this study. Of 93 patients, 42 patients received CHOPE, 40 patients with CHOP, and 11 patients with GDP regimen. RESULTS: Response could be evaluated in 88 of 93 patients at the end of primary treatment. The CR rate for patients received CHOP (n = 38), CHOPE (n = 39), and GDP (n = 11) were 28.9, 51.3, and 45.5%, respectively, (P = 0.132) with an ORR of 65.8, 76.9, and 90.9%, respectively, (P = 0.210). The median follow-up time was 17.1 (1.4-108.3) months. Median progression-free survival (PFS) in CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) groups were 6.0, 15.3, and 9.7 months (P = 0.094) with 1-year PFS of 35.0, 54.8, and 45.5%, respectively, (P = 0.078). One-year OS for patients received CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) were 65.0, 83.3, and 100%, respectively, (P = 0.013) (CHOP vs CHOPE, P = 0.030; CHOP vs GDP, P = 0.024; CHOPE vs GDP, P = 0.174). CONCLUSION: CHOPE has a trend to improve CR rate, 1-year PFS and OS compared with CHOP alone. GDP shows promising efficacy which worth further exploration in large cohort studies. Clinical experience presented in this study may serve as reference for future large cohort studies.
OBJECTIVES: Optimal chemotherapy regimen for peripheral T-cell lymphomas (PTCL) has not been fully defined. This study aimed to evaluate the optimal chemotherapy regimen in the first-line treatment for PTCL patients. METHODS: Between 2003 and 2014, 93 consecutive patients with PTCL were enrolled in this study. Of 93 patients, 42 patients received CHOPE, 40 patients with CHOP, and 11 patients with GDP regimen. RESULTS: Response could be evaluated in 88 of 93 patients at the end of primary treatment. The CR rate for patients received CHOP (n = 38), CHOPE (n = 39), and GDP (n = 11) were 28.9, 51.3, and 45.5%, respectively, (P = 0.132) with an ORR of 65.8, 76.9, and 90.9%, respectively, (P = 0.210). The median follow-up time was 17.1 (1.4-108.3) months. Median progression-free survival (PFS) in CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) groups were 6.0, 15.3, and 9.7 months (P = 0.094) with 1-year PFS of 35.0, 54.8, and 45.5%, respectively, (P = 0.078). One-year OS for patients received CHOP (n = 40), CHOPE (n = 42), and GDP (n = 11) were 65.0, 83.3, and 100%, respectively, (P = 0.013) (CHOP vs CHOPE, P = 0.030; CHOP vs GDP, P = 0.024; CHOPE vs GDP, P = 0.174). CONCLUSION: CHOPE has a trend to improve CR rate, 1-year PFS and OS compared with CHOP alone. GDP shows promising efficacy which worth further exploration in large cohort studies. Clinical experience presented in this study may serve as reference for future large cohort studies.
Authors: Mary Gleeson; Clare Peckitt; Ye Mong To; Laurice Edwards; Jacqueline Oates; Andrew Wotherspoon; Ayoma D Attygalle; Imene Zerizer; Bhupinder Sharma; Sue Chua; Ruwaida Begum; Ian Chau; Peter Johnson; Kirit M Ardeshna; Eliza A Hawkes; Marian P Macheta; Graham P Collins; John Radford; Adam Forbes; Alistair Hart; Silvia Montoto; Pamela McKay; Kim Benstead; Nicholas Morley; Nagesh Kalakonda; Yasmin Hasan; Deborah Turner; David Cunningham Journal: Lancet Haematol Date: 2018-05 Impact factor: 18.959